News

American Association of Individual Investors3h
Why Design Therapeutics, Inc.’s (DSGN) Stock Is Down 5.42%
Design Therapeutics, Inc.’s DSGN share price has dipped by 5.42%, which has investors questioning if this is right time to ...
Pharmabiz13h
UK MHRA grants marketing authorisation to Biogen’s omaveloxolone to treat Friedreich’s ataxia
UK MHRA grants marketing authorisation to Biogen’s omaveloxolone to treat Friedreich’s ataxia: United Kingdom Friday, April 25, 2025, 12:00 Hrs [IST] The Medicines and Healthc ...